- LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibition rate in MAT B III tumor bearing rats compared to anti-rPD-L1 alone
- LV UNO compares favorably to HV UNO administration in reducing tumor volumes in combination with anti-mPD-1 in CT26 BALB/c mice
- Increased nitro-tyrosine staining in LV UNO treated tumors indicates an improved distribution of UNO in the tumor leading to potentially improved outcomes and an enhanced safety profile
HAMILTON, Bermuda, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced key data demonstrating the efficacy of Low Volume UNO (LV UNO, < 100 mL) when combined with immune checkpoint inhibitors, which were presented in two posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024.
In a study using MAT B III tumor-bearing rats, LV UNO combined with anti-rPD-L1 doubled the tumor growth inhibition rate and led to improved survival outcomes compared to anti-rPD-L1 alone. These promising results support further clinical evaluation of LV UNO alongside checkpoint inhibitors for enhanced patient benefits and safety.
Additionally, LV UNO was shown to be more effective than High Volume UNO (HV UNO; 1 L) in reducing tumor volumes in CT26 BALB/c mice when paired with anti-mPD-1 treatment. Notably, LV UNO enhanced nitro-tyrosine staining, indicating better tumor distribution of nitric oxide and potentially improved safety outcomes.
Study Highlights:
Data presented in abstract #: 723, which is titled “Intratumoral Administration of Low Volume Ultra High Concentration Nitric Oxide and Anti-rPD-L1 Treatment Leads to Prolonged Survival in MAT B III Tumor-Bearing Rats,” demonstrated that doses of LV UNO at 25,000 ppm or 100,000 ppm combined with anti-rPD-L1 at 10 mg/kg led to a reduction in tumor volume as compared to anti-rPD-L1 only treated MAT B III bearing Fischer rats when dosed every third day for a total of six doses. Importantly, by Day 37 a prolonged survival advantage was observed in the LV UNO combination arm.
Dr. Jedidiah Monson, Chief Medical Officer of Beyond Cancer, commented, “Evaluating UNO alongside anti-rPD-L1 in MAT B III tumor bearing rats showed data that align with our previously published results in mice. As a result, we are excited to advance this program and evaluate LV UNO administration combined with checkpoint inhibitors in the clinic. We believe this approach could offer meaningful benefits for patients with the potential of an improved safety profile.”
LV UNO and Anti-rPD-L1 Doubled Survival by Day 37 versus Anti-rPD-L1 Alone
Caption: Anti-rPD-L1 mAb in combination with either 25,000 ppm or 100,000 ppm UNO resulted in prolonged survival
Data presented in abstract #: 724, which is titled “Intratumoral Administration of Low Volume Ultra-High Concentration Nitric Oxide and Immune Checkpoint Inhibitors in CT26 Tumor-Bearing Mice,” showed a greater reduction in primary tumor volume in mice receiving LV UNO in combination with anti-mPD-1 (n=25) at Day 11, compared to mice receiving HV UNO administration with anti-mPD-1 (n=14). Both combination treatment arms (HV UNO and LV UNO with anti-mPD-1) resulted in better tumor reduction than anti-mPD-1 alone (n=16). The enhanced effectiveness of the LV UNO administration method may be attributed, in part, to the improved distribution of UNO in the tumor, as measured by nitro-tyrosine immunohistochemistry staining following treatment. Nitro-tyrosine is a post translational modification product resulting from the reaction of tyrosine with reactive nitrogen species. HV UNO administration revealed Grade 1 staining, defined as a few positive cells [< 5 cells] versus Grade 3 staining, defined as a mild reaction [15–25 cells] for LV UNO administration (p < 0.01 compared to sham, ANOVA and Tukey HSD statistical methods). Tumors treated with sham or nitrogen showed the lowest levels of nitro-tyrosine staining.
Effect of LV UNO in Combination with Anti-mPD-1 mAb Reduced Primary Tumor Volume and Compares Favorably to HV UNO
Caption: LV UNO in Combination with Anti-mPD-1 mAb Reduced Primary CT26 Tumor Volume
“These preclinical results prompted our decision to commence the Phase 1b study to investigate the combination of LV UNO with immune checkpoint inhibitors. The clinical study aims to evaluate the potential of UNO to enhance the type, density, and distribution of immune cells within the tumor microenvironment, particularly in cases of PD-1 progression and prolonged stable disease,” stated Dr. Selena Chaisson, Chief Executive Officer, and Director of Beyond Cancer.
A copy of the ePublications can be accessed on the Science and Technology page of the Company’s website.
About Nitric Oxide
Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens.
About UNO Therapy for Solid Tumors
Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths. Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. Ultra-high concentration Nitric Oxide (UNO) therapy is a completely new approach to preventing relapse or metastatic disease. In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models. Beyond Cancer, Ltd. believes that UNO has the potential to prevent relapse or metastatic disease with as little as a single 5-minute treatment and with limited toxicity or off-target effects.
About Beyond Cancer, Ltd.
Beyond Cancer, Ltd. is a development-stage biopharmaceutical and medical device company utilizing ultra-high concentration nitric oxide (UNO) via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human study is underway in patients with solid tumors. Beyond Cancer is also conducting preclinical studies of UNO in multiple solid tumor models to inform additional treatment protocols. For more information, visit www.beyondcancer.com.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks forward,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials concerning the ultra-high concentration nitric oxide product candidate; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for the ultra-high concentration nitric oxide product candidate; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; obtaining, maintaining and protecting intellectual property utilized by products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air, Inc.’s website. Beyond Cancer and Beyond Air undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
[email protected]
(212) 915-2577
Matt Johnson, Head of Corporate Development & Strategy
Beyond Cancer, Ltd.
[email protected]
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/e845a3df-0d68-42e7-9a2a-1cb8e129bf5b
https://www.globenewswire.com/NewsRoom/AttachmentNg/798962a0-302e-4bc1-b063-b10b180fdc2a
